Nano Science and Technology Institute

NanoBio Corp. Closes Series B Funding Round

Company Reaches Its $22M Funding from Multiple Investor; Plans to Enter Several Clinical and Pre-Clinical Trials for Product Development

July 9, 2009

According to the company’s release, “’This investment round secures our ability to independently fund the next two years of our operations,” commented James R. Baker, Jr., MD, NanoBio’s CEO and founder.’” Funders for the Series B round include Perseus LLC and Venture Investors. NanoBio Corp. is a biopharmaceutical company developing dermatological products, anti-infective treatments and intranasal vaccines. The company’s dermatology and anti-infective product candidates include treatments for cold sores, onychomycosis (nail fungus), acne, and cystic fibrosis.

RSS feed of Nano World News

↑ Back to Nano World News™

© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map

Fatal error: Call to undefined function share_scripts() in /export/home/apache/httpd-nrc/docs/news/item.html on line 36